Geode Capital Management LLC Raises Holdings in ChromaDex Co. (NASDAQ:CDXC)

Geode Capital Management LLC increased its position in ChromaDex Co. (NASDAQ:CDXC) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,149,592 shares of the company’s stock after buying an additional 17,963 shares during the period. Geode Capital Management LLC owned 1.51% of ChromaDex worth $4,197,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC increased its stake in ChromaDex by 322.1% in the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after acquiring an additional 53,472 shares during the last quarter. Jane Street Group LLC increased its position in ChromaDex by 100.3% in the third quarter. Jane Street Group LLC now owns 45,712 shares of the company’s stock worth $167,000 after purchasing an additional 22,889 shares during the last quarter. State Street Corp raised its stake in ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after purchasing an additional 62,692 shares in the last quarter. MetLife Investment Management LLC raised its stake in ChromaDex by 39.3% during the third quarter. MetLife Investment Management LLC now owns 18,114 shares of the company’s stock valued at $66,000 after purchasing an additional 5,115 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in ChromaDex by 1,885.7% during the third quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock valued at $267,000 after purchasing an additional 69,582 shares during the last quarter. 15.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CDXC. HC Wainwright boosted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Roth Mkm boosted their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, StockNews.com lowered ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Friday.

Insider Activity

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares in the company, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 9.64% of the company’s stock.

ChromaDex Stock Up 0.5 %

CDXC stock opened at $5.51 on Monday. ChromaDex Co. has a twelve month low of $1.36 and a twelve month high of $7.97. The stock has a market capitalization of $420.87 million, a price-to-earnings ratio of 551.55 and a beta of 2.21. The firm’s fifty day simple moving average is $6.29 and its two-hundred day simple moving average is $4.25.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The company had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period in the prior year, the firm posted ($0.01) EPS. As a group, equities research analysts expect that ChromaDex Co. will post 0.04 EPS for the current year.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.